

Analysis of the Outcomes of the Screen-Time Reduction in Computer Vision Syndrome: A Cohort Comparative Study [Response to Letter]

Mohammed Iqbal , Ahmed Gad

Department of Ophthalmology, Faculty of Medicine, Sohag University, Sohag, Egypt

Correspondence: Mohammed Iqbal, Email dr_m_iqbal@yahoo.com

Dear editor

We thank both Dr. Abdelaziz K. and Dr. Shaheen M. for their interest in our study¹ in computer vision syndrome (CVS) and the important issues and questions they raised. For more precision and clarity, we would like to respond to their concerns in this reply and discuss the issues they addressed.

First, we did not publish and/or analyze all study data as we previously stated in the Discussion section; however, Table 1 shows the correlation between the daily screen-hours' differences and the differences in the other study outcome measures particularly uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), and multifocal electroretinogram (mfERG) Rings and Quadrants. Mathematically, we can simply define these differences as "the post-screen-time-reduction values – the pre-screen-time-reduction values". We exhibited a negative correlation between the differences of the daily screen-hours and UDVA, i.e. the lower the daily screen-hours the better the UDVA ($r=-0.61$, $P<0.0001$, Table 1). Furthermore, we also documented a positive correlation between the differences of the daily screen-hours reduction and mfERG Rings 1 and 2 with Quadrant 1, i.e. the more the daily screen-hours reduction the greater the foveal responses amplitude (amplitude density of the first foveal peak [P1 AD]) in R1, R2 and Q1 with more improved foveal peak close to normal ($r=0.53$, 0.51 and 0.38 ; $P=0.0001$, 0.0002

Table 1 Correlation Between Differences in Daily Screen-Hours and Study Parameters

Parameters	r (Correlation Coefficient)	P value
UDVA	-0.61	<0.0001*
CDVA	-0.25	0.08
Ring 1	0.53	0.0001
Ring 2	0.51	0.0002
Ring 3	0.26	0.06
Ring 4	0.04	0.80
Ring 5	0.15	0.38
Quadrant 1	0.38	0.006
Quadrant 2	-0.12	0.39
Quadrant 3	0.19	0.19
Quadrant 4	-0.05	0.74

Notes: bold value* signifies negative correlation; bold values signify positive correlation.

Table 2 Correlation between Differences in UDVA and mfERG Parameters

Parameters	r (Correlation Coefficient)	P value
Ring 1	-0.70	<0.0001
Ring 2	-0.49	0.0003
Ring 3	-0.40	0.004
Ring 4	-0.10	0.48
Ring 5	0.01	0.94
Quadrant 1	-0.53	0.0001
Quadrant 2	0.08	0.57
Quadrant 3	-0.37	0.009
Quadrant 4	0.11	0.43

Note: The bold values signify negative correlation.

Table 3 Correlation Between Differences in CDVA and mfERG Parameters

Parameters	r (Correlation Coefficient)	P value
Ring 1	-0.34	0.02
Ring 2	-0.38	0.007
Ring 3	-0.23	0.11
Ring 4	-0.06	0.69
Ring 5	-0.13	0.37
Quadrant 1	-0.35	0.01
Quadrant 2	0.11	0.46
Quadrant 3	-0.25	0.09
Quadrant 4	0.05	0.72

Note: The bold values signify negative correlation.

and 0.006, respectively; Table 1). Tables 2 and 3 summarize the correlation between UDVA and mfERG parameters, and CDVA and mfERG parameters, respectively. In short, there are negative correlations between many mfERG parameters and the mathematical “minus” sign of the logMAR units of pre- and post-screen-time reduction differences of both UDVA and CDVA, i.e. the more the improvements in the mfERG foveal responses, the more negative is the “-” sign of the logMAR differences’ units thus the better the improvements in both UDVA and CDVA (Tables 2 and 3). Therefore, we concluded that the improvements in the mfERG foveal responses were associated with corresponding improvements in the visual performances.

Second, regarding the concerns how we managed to observe these students, we definitely did not use surveillance cameras or observe them at their homes or colleges 24/7; however, we observed their objective outcomes that exhibited great improvements at the end of the study. Moreover, the students were free to quit at any time without trial completion. Therefore, we found no reason why the students did not follow our instructions especially if they were free to quit the trial anytime they wanted. Nevertheless, the improvement in their objective outcomes (UDVA, CDVA and mfERG foveal responses) at the end of the study coincided with the fact that they limited their screen-time to one hour daily for four weeks. Another similar example, when a doctor prescribes a diet regimen for an obese patient, the doctor cannot observe exactly what the patient eats at home or elsewhere; however the doctor measures the objective outcomes by observing the patient weight; once the patient follow the instructions, he/she starts to lose

weight. Furthermore, as we mentioned in the Discussion section, all participants responded to the CVS-F3 questionnaire,^{1–3} ([Supplementary Material](#)) twice at the beginning and the end of the study. Most of these participants reported marked improvements in their subjective CVS complaints especially with improvement of the visual blur and relieved eyestrain, headache, neck and shoulder pain. These subjective findings also proved the fact that the participants managed to reduce their screen-time to one screen-hour daily for four weeks. Nevertheless, we advised the participants to watch the TV screen from a proper distance of 5–6 meters and wear their spectacles if they had ones.

Third, we stated in the Methods section that the first step in recruitment of the students was to respond to our CVS-F3 questionnaire,^{1–3} ([Supplementary Material](#)) which includes an important question “Are you willing to decrease your screen hours to guard against CVS?” The students, who admitted that they were willing to decrease their screen-hours, were interviewed to convince them to participate in our trial to investigate the potential effect of the screen-time reduction in improving the screen-induced foveal dysfunction and visual performances. Therefore, although a large number of students responded to our CVS-F3 and we anticipated their participation, yet unfortunately only small number of them responded “Yes” as an answer to the later question. Among this small number, only students that fulfilled Iqbal’s four major diagnostic criteria for accurate CVS diagnosis,^{2,4} were included in the CVS group of the study.

Fourth, we think that our described instructions are generally applicable for all cases suffering from CVS complaints provided that they are really willing to reduce their screen-time.

Finally, we are grateful for the Editor-in-Chief and the Editorial Board for giving us the opportunity for this reply to respond to the concerns and issues addressed by Dr. Abdelaziz K and Dr. Shaheen M.

Acknowledgments

We are grateful for Professor Fouad Metry, the mathematician expert who analyzed the statistics in this reply.

Funding

There is no funding to report.

Disclosure

The authors report no conflicts of interest in this communication.

References

1. Iqbal M, Soliman A, Ibrahim O, Gad A. Analysis of the outcomes of the screen-time reduction in computer vision syndrome: a cohort comparative study. *Clin Ophthalmol.* 2023;17:123–134. doi:10.2147/OPHTH.S399044
2. Iqbal M, Said O, Ibrahim O, Soliman A. Visual sequelae of computer vision syndrome: a cross-sectional case-control study. *J Ophthalmol.* 2021;2021:6630286. doi:10.1155/2021/6630286
3. Iqbal M, Elzembely H, El-Massry A. Computer vision syndrome prevalence and ocular sequelae among medical students: a university-wide study on a marginalized visual security issue. *Open Ophthalmol J.* 2021;15:156–170. doi:10.2174/1874364102115010156
4. Iqbal M, Ibrahim Elzembely H, Said OM. Letter to the editor: “Self-reported student awareness and prevalence of computer vision syndrome during COVID-19 pandemic at Al-Baha University” [Letter]. *Clin Optim.* 2022;14:193–194. doi:10.2147/OPTO.S391171

Dove Medical Press encourages responsible, free and frank academic debate. The content of the Clinical Ophthalmology ‘letters to the editor’ section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Clinical Ophthalmology editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.

Clinical Ophthalmology

Dovepress

Publish your work in this journal

Clinical Ophthalmology is an international, peer-reviewed journal covering all subspecialties within ophthalmology. Key topics include: Optometry; Visual science; Pharmacology and drug therapy in eye diseases; Basic Sciences; Primary and Secondary eye care; Patient Safety and Quality of Care Improvements. This journal is indexed on PubMed Central and CAS, and is the official journal of The Society of Clinical Ophthalmology (SCO). The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/clinical-ophthalmology-journal>